Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease-Reference-Cited by-同舟云学术

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Published:2018-01-23 Issue:11 Volume:33 Page:2005-2011
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:

Author:

Dekkers Claire C J¹,Wheeler David C²,Sjöström C David³,Stefansson Bergur V³,Cain Valerie⁴,Heerspink Hiddo J L¹

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

2. Centre for Nephrology, University College London, London, UK

3. Department of Cardiovascular and metabolic diseases, Global Medicines Development, AstraZeneca, Gothenburg, Sweden

4. Department of Biometrics and Information Sciences, Bogier Clinical and IT Solutions, Raleigh, NC, USA

Funder

AstraZeneca

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/33/11/2005/26293805/gfx350.pdf

Reference31 articles.

1. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging;Bailey;BMC Res Notes,2014

2. Kidney disease and increased mortality risk in type 2 diabetes;Afkarian;J Am Soc Nephrol,2013

3. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications;Heerspink;Circulation,2016

4. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin–angiotensin blockers;Heerspink;Diabetes Obes Metab,2016

5. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists;Frontiers in Medicine;2024-06-19

2. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease;Annals of Internal Medicine;2024-06

3. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

4. Chronic Kidney Disease in the Older Adult Patient with Diabetes;Journal of Clinical Medicine;2024-01-08

5. Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis;BMC Gastroenterology;2023-12-19